Dyne Therapeutics Inc (DYN)

$8.17 +0.34 (4.34%)
Market Cap 928.39M
Revenue (ttm) 0.00
Net Income (ttm) -317.42M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,315,600
Avg Vol 2,036,592
Day's Range N/A - N/A
Shares Out 113.63M
Stochastic %K 90%
Beta 1.21
Analysts Strong Sell
Price Target $47.86

Latest News on DYN

Dyne Therapeutics Announces Chief Business Officer and Chief Scientific Officer Appointments

Apr 15, 2025, 7:30 AM EDT - 5 days ago

Dyne Therapeutics Announces Chief Business Officer and Chief Scientific Officer Appointments

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apr 14, 2025, 4:30 PM EDT - 6 days ago

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Financial Officer

Mar 20, 2025, 4:30 PM EDT - 4 weeks ago

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Financial Officer

Dyne Therapeutics Announces Appointment of Erick J. Lucera as Chief Financial Officer

Mar 20, 2025, 4:10 PM EDT - 4 weeks ago

Dyne Therapeutics Announces Appointment of Erick J. Lucera as Chief Financial Officer

Dyne Therapeutics Announces New Long-Term Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented and Sustained Functional Improvement Through 18 Months

Mar 16, 2025, 7:00 PM EDT - 5 weeks ago

Dyne Therapeutics Announces New Long-Term Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented and Sustained Functional Improvement Through 18 Months

Dyne: Accelerated Approval Of DYNE-101 Might Be Possible With Surrogate Biomarker

Mar 13, 2025, 9:09 AM EDT - 5 weeks ago

Dyne: Accelerated Approval Of DYNE-101 Might Be Possible With Surrogate Biomarker

Dyne Therapeutics' $4.3 Billion Peak Sales Potential? Analyst Highlights Key Strengths And Risks

Mar 12, 2025, 3:05 PM EDT - 5 weeks ago

Dyne Therapeutics' $4.3 Billion Peak Sales Potential? Analyst Highlights Key Strengths And Risks

Dyne Therapeutics to Present at Stifel 2025 Virtual CNS Forum

Mar 11, 2025, 7:30 AM EDT - 5 weeks ago

Dyne Therapeutics to Present at Stifel 2025 Virtual CNS Forum

Dyne Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

Feb 27, 2025, 7:30 AM EST - 7 weeks ago

Dyne Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

Dyne Therapeutics Announces Upcoming Presentations at the 2025 MDA Clinical & Scientific Conference

Feb 14, 2025, 4:05 PM EST - 2 months ago

Dyne Therapeutics Announces Upcoming Presentations at the 2025 MDA Clinical & Scientific Conference

Dyne Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 3, 2025, 7:30 AM EST - 2 months ago

Dyne Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

Dyne Therapeutics Receives FDA Fast Track Designation for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1

Jan 21, 2025, 7:30 AM EST - 3 months ago

Dyne Therapeutics Receives FDA Fast Track Designation for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1

Why Is Neuromuscular-Focused Dyne Therapeutics Stock Trading Lower On Friday?

Jan 10, 2025, 1:40 PM EST - 3 months ago

Why Is Neuromuscular-Focused Dyne Therapeutics Stock Trading Lower On Friday?

Dyne Therapeutics Reports New Clinical Data Showing Compelling Impact on Multiple Measures of Myotonic Dystrophy Type 1 (DM1); Dyne Plans to Initiate Registrational Expansion Cohort to Support Potential Submission for U.S. Accelerated Approval for DYNE-101 in DM1 in H1 2026

Jan 10, 2025, 6:30 AM EST - 3 months ago

Dyne Therapeutics Reports New Clinical Data Showing Compelling Impact on Multiple Measures of Myotonic Dystrophy Type 1 (DM1); Dyne Plans to Initiate Registrational Expansion Cohort to Support Potential Submission for U.S. Accelerated Approval for DYNE-101 in DM1 in H1 2026

Dyne Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference

Jan 9, 2025, 7:30 AM EST - 3 months ago

Dyne Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference

Dyne Therapeutics to Host Investor Conference Call and Webcast to Review New Clinical Data from the ACHIEVE Trial Friday, January 10 at 8:00 a.m. ET

Jan 8, 2025, 4:05 PM EST - 3 months ago

Dyne Therapeutics to Host Investor Conference Call and Webcast to Review New Clinical Data from the ACHIEVE Trial Friday, January 10 at 8:00 a.m. ET

Dyne Therapeutics' Q3 Preview: High-Risk, High-Reward Path In Muscle Diseases

Nov 11, 2024, 6:15 PM EST - 5 months ago

Dyne Therapeutics' Q3 Preview: High-Risk, High-Reward Path In Muscle Diseases

Dyne Therapeutics to Present at Upcoming Investor Conferences

Nov 7, 2024, 4:15 PM EST - 5 months ago

Dyne Therapeutics to Present at Upcoming Investor Conferences

Dyne Therapeutics Inc Is Being Investigated For Securities Fraud And Affected Shareholders Are Urged To Contact The Schall Law Firm

Nov 3, 2024, 11:00 AM EST - 6 months ago

Dyne Therapeutics Inc Is Being Investigated For Securities Fraud And Affected Shareholders Are Urged To Contact The Schall Law Firm

Dyne Therapeutics Inc Is Being Sued For Securities Fraud And Shareholders With Losses Are Urged To Contact The Schall Law Firm

Oct 31, 2024, 11:00 AM EDT - 6 months ago

Dyne Therapeutics Inc Is Being Sued For Securities Fraud And Shareholders With Losses Are Urged To Contact The Schall Law Firm

Dyne Therapeutics Inc May Have Committed Securities Fraud And Stockholders With Losses Are Urged To Reach Out To The Schall Law Firm

Oct 29, 2024, 11:00 AM EDT - 6 months ago

Dyne Therapeutics Inc May Have Committed Securities Fraud And Stockholders With Losses Are Urged To Reach Out To The Schall Law Firm

Dyne Therapeutics Inc Is Being Investigated For Securities Fraud And Shareholders With Losses Are Urged To Contact The Schall Law Firm

Oct 26, 2024, 11:00 AM EDT - 6 months ago

Dyne Therapeutics Inc Is Being Investigated For Securities Fraud And Shareholders With Losses Are Urged To Contact The Schall Law Firm

Dyne Therapeutics Inc Is Being Investigated For Securities Fraud And Impacted Shareholders Are Urged To Contact The Schall Law Firm

Oct 20, 2024, 11:00 AM EDT - 6 months ago

Dyne Therapeutics Inc Is Being Investigated For Securities Fraud And Impacted Shareholders Are Urged To Contact The Schall Law Firm

The Schall Law Firm Encourages Investor Participation In An Inquiry Into Dyne Therapeutics, Inc. For Securities Related Infractions

Oct 17, 2024, 11:00 AM EDT - 6 months ago

The Schall Law Firm Encourages Investor Participation In An Inquiry Into Dyne Therapeutics, Inc. For Securities Related Infractions

Dyne Therapeutics Inc Is Being Investigated For Possible Securities Fraud And Affected Shareholders Are Urged To Contact The Schall Law Firm

Oct 16, 2024, 11:00 AM EDT - 6 months ago

Dyne Therapeutics Inc Is Being Investigated For Possible Securities Fraud And Affected Shareholders Are Urged To Contact The Schall Law Firm

Dyne Therapeutics Inc Is Being Investigated For Possible Securities Fraud And Affected Shareholders Are Urged To Help The Schall Law Firm

Oct 14, 2024, 11:00 AM EDT - 6 months ago

Dyne Therapeutics Inc Is Being Investigated For Possible Securities Fraud And Affected Shareholders Are Urged To Help The Schall Law Firm

Dyne Therapeutics Presents Data at World Muscle Society Congress Highlighting Promise of FORCE™ Platform to Address Underlying Causes of Neuromuscular Diseases

Oct 9, 2024, 7:30 AM EDT - 6 months ago

Dyne Therapeutics Presents Data at World Muscle Society Congress Highlighting Promise of FORCE™ Platform to Address Underlying Causes of Neuromuscular Diseases

The Schall Law Firm Invites Investor Participation In An Inquiry Into Dyne Therapeutics, Inc. For Violating Securities Laws

Sep 29, 2024, 11:00 AM EDT - 7 months ago

The Schall Law Firm Invites Investor Participation In An Inquiry Into Dyne Therapeutics, Inc. For Violating Securities Laws

Dyne Therapeutics Inc Is Being Investigated For Possible Securities Fraud And Impacted Shareholders Are Encouraged To Contact The Schall Law Firm

Sep 28, 2024, 11:00 AM EDT - 7 months ago

Dyne Therapeutics Inc Is Being Investigated For Possible Securities Fraud And Impacted Shareholders Are Encouraged To Contact The Schall Law Firm

The Schall Law Firm Urges Investor Participation In An Inquiry Into Dyne Therapeutics, Inc. For Violating Securities Laws

Sep 27, 2024, 11:00 AM EDT - 7 months ago

The Schall Law Firm Urges Investor Participation In An Inquiry Into Dyne Therapeutics, Inc. For Violating Securities Laws

Dyne Therapeutics Inc Is Being Investigated By The Schall Law Firm For Securities Fraud And Stockholders Are Invited To Reach Out

Sep 26, 2024, 11:00 AM EDT - 7 months ago

Dyne Therapeutics Inc Is Being Investigated By The Schall Law Firm For Securities Fraud And Stockholders Are Invited To Reach Out

The Schall Law Firm Is Looking Into Dyne Therapeutics, Inc. For Violating Securities Laws And Impacted Investors Should Join The Inquiry

Sep 25, 2024, 11:00 AM EDT - 7 months ago

The Schall Law Firm Is Looking Into Dyne Therapeutics, Inc. For Violating Securities Laws And Impacted Investors Should Join The Inquiry

Dyne Therapeutics Inc Is Being Investigated For Possible Securities Fraud And Stockholders With Losses Are Urged To Contact The Schall Law Firm

Sep 24, 2024, 11:00 AM EDT - 7 months ago

Dyne Therapeutics Inc Is Being Investigated For Possible Securities Fraud And Stockholders With Losses Are Urged To Contact The Schall Law Firm

Dyne Therapeutics to Present at Chardan's 8th Annual Genetic Medicines Conference

Sep 23, 2024, 8:56 AM EDT - 7 months ago

Dyne Therapeutics to Present at Chardan's 8th Annual Genetic Medicines Conference

Shareholders Should Help The Schall Law Firm Investigate Whether Dyne Therapeutics Inc Committed Securities Fraud

Sep 22, 2024, 11:00 AM EDT - 7 months ago

Shareholders Should Help The Schall Law Firm Investigate Whether Dyne Therapeutics Inc Committed Securities Fraud

Dyne Therapeutics Inc May Have Engaged In Securities Fraud And The Schall Law Firm Wants Shareholders To Contribute To An Investigation

Sep 20, 2024, 11:00 AM EDT - 7 months ago

Dyne Therapeutics Inc May Have Engaged In Securities Fraud And The Schall Law Firm Wants Shareholders To Contribute To An Investigation

Bronstein, Gewirtz & Grossman, LLC Encourages Dyne Therapeutics, Inc. (DYN) Shareholders to Inquire about Securities Investigation

Sep 19, 2024, 10:00 AM EDT - 7 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Dyne Therapeutics, Inc. (DYN) Shareholders to Inquire about Securities Investigation

Dyne Therapeutics Inc Is Being Investigated For Securities Fraud And The Schall Law Firm Wants Impacted Shareholders To Reach Out

Sep 18, 2024, 11:00 AM EDT - 7 months ago

Dyne Therapeutics Inc Is Being Investigated For Securities Fraud And The Schall Law Firm Wants Impacted Shareholders To Reach Out

Bronstein, Gewirtz & Grossman, LLC Is Investigating Dyne Therapeutics, Inc. (DYN) And Encourages Shareholders to Connect

Sep 18, 2024, 10:00 AM EDT - 7 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Dyne Therapeutics, Inc. (DYN) And Encourages Shareholders to Connect

The Schall Law Firm Is Looking Into Dyne Therapeutics, Inc. For Securities Related Infractions And Investors Are Invited To Join The Inquiry

Sep 17, 2024, 11:00 AM EDT - 7 months ago

The Schall Law Firm Is Looking Into Dyne Therapeutics, Inc. For Securities Related Infractions And Investors Are Invited To Join The Inquiry